Skip to main content
vTv Therapeutics Inc. logo

vTv Therapeutics Inc. — Investor Relations & Filings

Ticker · VTVT ISIN · US9183852048 LEI · 549300WQE5EI9R35SE66 US Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2024-08-08 Earnings Release
Country US United States of America
Listing US VTVT

About vTv Therapeutics Inc.

https://vtvtherapeutics.com/

vTv Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. The company's primary commitment is to improving the lives of patients with diabetes. Its lead clinical drug candidate is cadisegliatin, a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. In collaboration with development partners, vTv is also pursuing additional indications for its pipeline molecules, including type 2 diabetes and other chronic conditions.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 8, 2024, by vTv Therapeutics Inc. It announces the issuance of a press release reporting financial results for the fiscal quarter ended June 30, 2024. The document itself does not contain the financial results but references an attached press release (Exhibit 99.1) that announces these results. The length of the document is 3712 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, since this document announces the release of financial results and includes a press release as an exhibit, it should be classified as an Earnings Release (ER). The Form 8-K is commonly used for such announcements. Therefore, the appropriate classification is ER with high confidence.
2024-08-08 English
10-Q
Interim / Quarterly Report Q2 2024
2024-08-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions an "Other Events" section where the company announces a press release about a clinical hold on a program. The document is short (3272 characters) and primarily serves to announce this event and attach the press release as an exhibit. There are no financial statements or detailed financial data included. This fits the profile of a Regulatory Filing (RNS), which is a general regulatory announcement that does not fit into more specific categories like Annual Report or Earnings Release. The document is not a full report but an announcement of an event, so it is not classified as a financial report type.
2024-07-26 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report under the Securities Exchange Act of 1934. It reports the entry into a material definitive agreement (a Second Amendment to a License Agreement) by the company. The document does not contain financial statements or detailed financial analysis but rather announces a significant contractual event. The length is 3785 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-07-02 English
4
Director's Dealing
2024-06-27 English
FORM 4
Director's Dealing
2024-06-27 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.